158 related articles for article (PubMed ID: 34131807)
1. Evaluation of efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC.
Wang Y; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Wu D; Long J; Zhang Z; Fang J
Cancer Immunol Immunother; 2022 Feb; 71(2):267-276. PubMed ID: 34131807
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
Corral J; Majem M; Rodríguez-Abreu D; Carcereny E; Cortes ÁA; Llorente M; López Picazo JM; García Y; Domine M; López Criado MP
Clin Transl Oncol; 2019 Sep; 21(9):1270-1279. PubMed ID: 30771085
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Patil PD; Shapiro M; Hashemi Sadraei N; Pennell NA
Oncologist; 2019 Apr; 24(4):457-e126. PubMed ID: 30602615
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of subsequent docetaxel +/- ramucirumab and S-1 after nivolumab for patients with advanced non-small cell lung cancer.
Tamura N; Horinouchi H; Sekine K; Matsumoto Y; Murakami S; Goto Y; Kanda S; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2019 May; 10(5):1141-1148. PubMed ID: 30913364
[TBL] [Abstract][Full Text] [Related]
10. Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Shiono A; Kaira K; Mouri A; Yamaguchi O; Hashimoto K; Uchida T; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):775-781. PubMed ID: 30809973
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
12. A Randomized Comparison of Nivolumab versus Nivolumab + Docetaxel for Previously Treated Advanced or Recurrent ICI-Naïve Non-Small Cell Lung Cancer: TORG1630.
Taniguchi Y; Shimokawa T; Takiguchi Y; Misumi T; Nakamura Y; Kawashima Y; Furuya N; Shiraishi Y; Harada T; Tanaka H; Miura S; Uchiyama A; Nakahara Y; Tokito T; Naoki K; Bessho A; Goto Y; Seike M; Okamoto H
Clin Cancer Res; 2022 Oct; 28(20):4402-4409. PubMed ID: 35980349
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.
Peters S; Stahel RA; Dafni U; Ponce Aix S; Massutí B; Gautschi O; Coate L; López Martín A; van Heemst R; Berghmans T; Meldgaard P; Cobo Dols M; Garde Noguera J; Curioni-Fontecedro A; Rauch D; Mark MT; Cuffe S; Biesma B; van Henten AMJ; Juan Vidal Ó; Palmero Sanchez R; Villa Guzmán JC; Collado Martin R; Peralta S; Insa A; Summers Y; Láng I; Horgan A; Ciardiello F; de Hosson S; Pieterman R; Groen HJM; van den Berg PM; Zielinski CC; Chittazhathu Kurian Kuruvilla Y; Gasca-Ruchti A; Kassapian M; Novello S; Torri V; Tsourti Z; Gregorc V; Smit EF;
J Thorac Oncol; 2017 Apr; 12(4):752-762. PubMed ID: 28017787
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness of Nivolumab Monotherapy After Prior Systemic Therapy in Advanced Non-Small-Cell Lung Cancer in the United States.
Stenehjem DD; Lubinga SJ; Gupte-Singh K; Zhang Y; Le TK; Penrod JR; Smith CB
Clin Lung Cancer; 2021 Jan; 22(1):e35-e47. PubMed ID: 33187914
[TBL] [Abstract][Full Text] [Related]
16. Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial.
Pu X; Xiao Z; Li J; Wu Z; Ma Z; Weng J; Xiao M; Chen Y; Cao Y; Cao P; Wang Q; Xu Y; Li K; Chen B; Xu F; Liu L; Kong Y; Zhang H; Duan H; Wu L
Lung Cancer; 2024 May; 191():107538. PubMed ID: 38552544
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
Lu S; Wang J; Cheng Y; Mok T; Chang J; Zhang L; Feng J; Tu HY; Wu L; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Ying K; Zhong H; Poddubskaya E; Soo RA; Chia YH; Li A; Li A; Wu YL
Lung Cancer; 2021 Feb; 152():7-14. PubMed ID: 33321441
[TBL] [Abstract][Full Text] [Related]
18. Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
Zhang Y; Song L; Zeng L; Xiong Y; Liu L; Zhou C; Yang H; Wang Z; Xia Q; Jiang W; Xu Q; Yang N
BMC Cancer; 2022 Sep; 22(1):952. PubMed ID: 36064386
[TBL] [Abstract][Full Text] [Related]
19. Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis.
Yi Y; Liu Z; Fang L; Li J; Liu W; Wang F; Fu P; Xie C; Liu J; Song B
Cancer Chemother Pharmacol; 2020 Jul; 86(1):65-74. PubMed ID: 32533335
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]